Citigroup Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs (NASDAQ:ESTA - Get Free Report) had its target price hoisted by equities research analysts at Citigroup from $38.00 to $47.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a "neutral" rating on the stock. Citigroup's price objective would suggest a potential upside of 4.31% from the stock's previous close.

A number of other equities research analysts have also recently commented on ESTA. BTIG Research initiated coverage on Establishment Labs in a report on Friday, May 16th. They set a "buy" rating and a $62.00 price target on the stock. Wall Street Zen raised Establishment Labs from a "sell" rating to a "hold" rating in a report on Saturday, June 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $48.00 price target on shares of Establishment Labs in a report on Friday, June 13th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $51.80.

Establishment Labs Trading Up 2.5%

Shares of NASDAQ ESTA traded up $1.09 during midday trading on Wednesday, reaching $45.06. The company had a trading volume of 335,816 shares, compared to its average volume of 477,533. Establishment Labs has a one year low of $26.56 and a one year high of $52.41. The company has a quick ratio of 2.05, a current ratio of 3.36 and a debt-to-equity ratio of 5.72. The firm's fifty day moving average price is $37.39 and its 200-day moving average price is $36.89. The stock has a market cap of $1.30 billion, a PE ratio of -14.54 and a beta of 0.80.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.13. The firm had revenue of $41.38 million during the quarter, compared to analyst estimates of $41.15 million. Establishment Labs had a negative return on equity of 196.25% and a negative net margin of 52.34%. The business's revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.58) EPS. On average, equities research analysts anticipate that Establishment Labs will post -2.41 earnings per share for the current year.

Institutional Trading of Establishment Labs

Several institutional investors have recently added to or reduced their stakes in the company. Mudita Advisors LLP raised its stake in shares of Establishment Labs by 15.6% during the first quarter. Mudita Advisors LLP now owns 479,359 shares of the company's stock valued at $19,560,000 after acquiring an additional 64,859 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Establishment Labs by 20.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company's stock valued at $2,335,000 after buying an additional 9,557 shares during the last quarter. Boothbay Fund Management LLC grew its holdings in shares of Establishment Labs by 0.6% during the first quarter. Boothbay Fund Management LLC now owns 528,308 shares of the company's stock valued at $21,558,000 after buying an additional 3,060 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in Establishment Labs in the first quarter valued at $326,000. Finally, Redmile Group LLC boosted its holdings in Establishment Labs by 4.8% in the first quarter. Redmile Group LLC now owns 335,366 shares of the company's stock valued at $13,685,000 after purchasing an additional 15,217 shares during the last quarter. Institutional investors own 72.91% of the company's stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.